Bank of New York Mellon’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-880
| Closed | -$5.28K | – | 4409 |
|
|
2023
Q3 | $5.28K | Hold |
880
| – | – | ﹤0.01% | 4326 |
|
|
2023
Q2 | $6.07K | Hold |
880
| – | – | ﹤0.01% | 4364 |
|
|
2023
Q1 | $13.8K | Hold |
880
| – | – | ﹤0.01% | 4333 |
|
|
2022
Q4 | $17.6K | Hold |
880
| – | – | ﹤0.01% | 4371 |
|
|
2022
Q3 | $16K | Hold |
880
| – | – | ﹤0.01% | 4477 |
|
|
2022
Q2 | $20K | Sell |
880
-5,941
| -87% | -$132K | ﹤0.01% | 4493 |
|
|
2022
Q1 | $190K | Sell |
6,821
-182
| -3% | -$6.62K | ﹤0.01% | 4263 |
|
|
2021
Q4 | $318K | Buy |
7,003
+114
| +2% | +$7.67K | ﹤0.01% | 4062 |
|
|
2021
Q3 | $575K | Buy |
6,889
+486
| +8% | +$40.2K | ﹤0.01% | 3730 |
|
|
2021
Q2 | $608K | Buy |
6,403
+5,523
| +628% | +$655K | ﹤0.01% | 3684 |
|
|
2021
Q1 | $146K | Sell |
880
-90
| -9% | -$11.9K | ﹤0.01% | 4114 |
|
|
2020
Q4 | $95K | Buy |
+970
| New | +$61.4K | ﹤0.01% | 4079 |
|
|
2019
Q3 | – | Sell |
-851
| Closed | -$113K | – | 4268 |
|
|
2019
Q2 | $113K | Buy |
851
+737
| +646% | +$114K | ﹤0.01% | 4011 |
|
|
2019
Q1 | $19K | Sell |
114
-1
| -0.9% | -$149 | ﹤0.01% | 4165 |
|
|
2018
Q4 | $12K | Sell |
115
-125
| -52% | -$25K | ﹤0.01% | 4187 |
|
|
2018
Q3 | $53K | Buy |
240
+19
| +9% | +$45.6K | ﹤0.01% | 4113 |
|
|
2018
Q2 | $474K | Buy |
221
+53
| +32% | +$134K | ﹤0.01% | 3656 |
|
|
2018
Q1 | $417K | Buy |
168
+5
| +3% | +$11.1K | ﹤0.01% | 3665 |
|
|
2017
Q4 | $291K | Sell |
163
-4
| -2% | -$5.79K | ﹤0.01% | 3812 |
|
|
2017
Q3 | $197K | Hold |
167
| – | – | ﹤0.01% | 3880 |
|
|
2017
Q2 | $124K | Buy |
+167
| New | +$102K | ﹤0.01% | 3983 |
|
|
2016
Q4 | – | Sell |
-25
| Closed | -$27K | – | 4323 |
|
|
2016
Q3 | $27K | Sell |
25
-3
| -11% | -$2.62K | ﹤0.01% | 4201 |
|
|
2016
Q2 | $22K | Hold |
28
| – | – | ﹤0.01% | 4260 |
|
|
2016
Q1 | $20K | Hold |
28
| – | – | ﹤0.01% | 4170 |
|
|
2015
Q4 | $28K | Hold |
28
| – | – | ﹤0.01% | 4247 |
|
|
2015
Q3 | $30K | Hold |
28
| – | – | ﹤0.01% | 4296 |
|
|
2015
Q2 | $58K | Buy |
28
+3
| +12% | +$4.26K | ﹤0.01% | 4149 |
|
|
2015
Q1 | $24K | Hold |
25
| – | – | ﹤0.01% | 4188 |
|
|
2014
Q4 | $25K | Hold |
25
| – | – | ﹤0.01% | 4202 |
|
|
2014
Q3 | $26K | Hold |
25
| – | – | ﹤0.01% | 4190 |
|
|
2014
Q2 | $48K | Sell |
25
-65
| -72% | -$129K | ﹤0.01% | 4077 |
|
|
2014
Q1 | $193K | Hold |
90
| – | – | ﹤0.01% | 3855 |
|
|
2013
Q4 | $209K | Buy |
90
+1
| +1% | +$2.29K | ﹤0.01% | 3844 |
|
|
2013
Q3 | $251K | Buy |
89
+1
| +1% | +$4.98K | ﹤0.01% | 3725 |
|
|
2013
Q2 | $808K | Buy |
+88
| New | +$678K | ﹤0.01% | 3294 |
|
Other funds holding ONCT
PPW
RB
IC
Bank of New York Mellon's ONCT Position: Q4 2023 in Review
Bank of New York Mellon sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q4 2023, closing a stake of 880 shares — an estimated $5.28K sold.
Bank of New York Mellon first reported a position in ONCT in Q2 2013 and held it in 35 quarters. The position peaked at $808K in Q2 2013. 38 funds tracked by Wall St. Rank hold ONCT as of Q4 2023.
- Bank of New York Mellon reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
- Bank of New York Mellon sold 880 Oncternal Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $5.28K.
- Bank of New York Mellon first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q2 2013 and held it in 35 quarters.
- Bank of New York Mellon's Oncternal Therapeutics, Inc. Common Stock position peaked at $808K in Q2 2013.
- 38 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q4 2023.
Based on Bank of New York Mellon's 13F filing for Q4 2023, filed 29 Jan 2024.